Treatment of visual impairment associated with chronic
diabetic macular oedema which is insufficiently
responsive to available therapies (specialist use only) |
Prevention of relapse in recurrent non-infectious uveitis
affecting the posterior segment of the eye (specialist use
only)
▶BY INTRAVITREAL INJECTION
▶Adult: 190 micrograms, to be administered into the
affected eye, concurrent administration to both eyes
not recommended. For further information on pre-
treatment, administration and repeat dosing, consult
product literature
PDF page 1278
Active or suspected ocular infection
. active or suspected peri-ocular infection. pre-existing
glaucoma
PDF page 1278
Raised baseline intra-ocular pressure
PDF page 1278
NICE decisions
▶Fluocinolone acetonide intravitreal implant for treating
chronic diabetic macular oedema after an inadequate
response to prior therapy (November 2013) NICE TA301
Fluocinolone acetonide intravitreal implant (Iluvien ®) is
recommended as an option for treating chronic diabetic
macular oedema that is insufficiently responsive to
available therapies only if:
. the implant is to be used in an eye with an intra-ocular
(pseudophakic lens), and
. the manufacturer provides fluocinolone acetonide
intravitreal implant with the discount agreed in the
patient access scheme.
www.nice.org.uk/guidance/ta301
▶Fluocinolone acetonide intravitreal implant for treating
chronic diabetic macular oedema in phakic eyes after an
inadequate response to previous therapy (November 2019)
NICE TA613
Fluocinolone acetonide intravitreal implant (Iluvien ®) is
not recommended as an option for treating chronic
diabetic macular oedema that is insufficiently responsive
to available therapies in an eye with a natural lens (phakic
eye).
Patients whose treatment was started within the NHS
before this guidance was published should have the option
to continue treatment, without change to their funding
arrangements, until they and their NHS clinician consider
it appropriate to stop.
www.nice.org.uk/guidance/ta613
▶Fluocinolone acetonide intravitreal implant for treating
recurrent non-infectious uveitis (July 2019) NICE TA590
Fluocinolone acetonide intravitreal implant (Iluvien ®) is
recommended, within its marketing authorisation, as an
option for preventing relapse in recurrent non-infectious
uveitis affecting the posterior segment of the eye. It is
recommended only if the manufacturer provides it
according to the commercial arrangement.
www.nice.org.uk/guidance/ta590
Scottish Medicines Consortium (SMC) decisions
SMC No. 864/13
The Scottish Medicines Consortium has advised (February
2014) that fluocinolone acetonide intravitreal implant
(Iluvien ®) is recommended for restricted use within NHS
Scotland for the treatment of vision impairment associated
with chronic diabetic macular oedema, considered
insufficiently responsive to available therapies, only in
patients in whom the affected eye is pseudophakic (has an
artificial lens after cataract surgery), and retreatment
would take place only if the patient had previously
responded to treatment with fluocinolone acetonide and
subsequently best corrected visual acuity had deteriorated
to less than 20/32. This advice is contingent upon the
continuing availability of the patient access scheme in
NHS Scotland or a list price that is equivalent or lower.
PDF pages 1278, 1279
